key: cord-0791913-jkpcq7ja authors: Radwi, Mansoor; Farsi, Sara title: A case report of acquired hemophilia following COVID‐19 vaccine date: 2021-05-10 journal: J Thromb Haemost DOI: 10.1111/jth.15291 sha: 0959712a76597d39f2cb662eeac35ba1ee18528a doc_id: 791913 cord_uid: jkpcq7ja Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69‐year‐old gentleman who developed bleeding symptoms after receiving COVID‐19 vaccine. Laboratory testing showed isolated prolongation of the activated partial thromboplastin time, and normal von Willebrand factor. Further testing confirmed the presence of factor VIII inhibitor. To date, no cases of AHA have been reported after exposure to COVID‐19 vaccine. There have been two cases of AHA following seasonal flu and H1N1 vaccination, as well as two cases of AHA following COVID‐19 infection. We present a summary of these cases and review of literature of autoimmune reactions following vaccination. Acquired hemophilia A (AHA) is a bleeding condition in which patients develop autoantibodies directed against clotting factor VIII (FVIII). 1 AHA is a rare disorder, with an incidence of around 1 per million. 2 Patients with AHA are often elderly, except for female patients who tend to be young and are either pregnant or postpartum. Comorbidities such as autoimmune disease and cancers are commonly associated with AHA. 3 Bleeding in AHA most commonly involves the skin. Deep tissue bleeding (e.g., joints) is not as common compared to congenital hemophilia A. 3 Few cases have reported infection or vaccination as a possible trigger for AHA. [4] [5] [6] We report on a case of AHA following a Pfizer-BioNTech SARS CoV-2 mRNA vaccine. A 69-year-old gentleman presented with a history of mild bruising on his left wrist, 9 days after receiving the first dose of COVID-19 vaccine. He gave no personal or family history of any bleeding disorders. Following the second dose of COVID-19, he noticed several new bruises appearing on his arms and legs. All the bruises were spontaneous except for a significant bruise associated with swelling on his right thigh following minor trauma, which continued to expand over the next 2 days. He also received an intramuscular injection in his thigh, which resulted in localized swelling associated with pain upon walking. His comorbidities in- Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69-year-old gentleman who developed bleeding symptoms after receiving COVID-19 vaccine. Laboratory testing showed isolated prolongation of the activated partial thromboplastin time, and normal von Willebrand factor. Further testing confirmed the presence of factor VIII inhibitor. To date, no cases of AHA have been reported after exposure to COVID-19 vaccine. There have been two cases of AHA following seasonal flu and H1N1 vaccination, as well as two cases of AHA following COVID-19 infection. We present a summary of these cases and review of literature of autoimmune reactions following vaccination. In addition, we found two cases of AHA associated with vaccination. The first case involved a 72-year-old woman who experienced bruising 8 days after receiving a seasonal influenza vaccine. The second case involved a 66-year-old woman who developed ecchymoses 20 days post H1N1 vaccination. Both cases revealed low FVIII and presence of FVIII inhibitors. Both patients were treated with steroids; however, in the first case, due to non-responsiveness, rituximab was added to achieve remission. The pathophysiology of AHA is unclear, although it is thought that T-lymphocytes and certain genetic polymorphisms may play a role. 8 Vaccines have long been implicated in generating autoantibodies. It has been suggested that vaccination may trigger an autoimmune response due to antigenic mimicry as well as due to activation of quiescent auto-reactive T and B cells. 9 15 Guillain-Barre syndrome, 16 and immune thrombocytopenic purpura. 17 There have been more than 200 million COVID-19 vaccine doses administered and 43.6 million individuals are deemed fully vaccinated worldwide. 18 The most common side effects reported with COVID-19 vaccine are pain at injection side, fever, chills, arthralgia, myalgia, and headache. 19 Anaphylaxis, the most serious side effect reported with vaccines, is extremely rare (11.1 cases per million doses). 20 We, the authors, acknowledge that it is difficult to confirm a definitive link between COVID-19 vaccine and AHA, and the emergence of FVIII inhibitors post vaccination is most likely be a coincidence; however, it is plausible that a link may exist and is supported by: (1) the fact that the patient did not have usual diseases commonly associated with AHA, for example, presence of active solid malignancy or autoimmune disease and (2) several case reports have suggested that COVID-19 infection and vaccines in general may trigger an autoimmune reaction. It is important to emphasize that clinical trials involving COVID-19 vaccines will fail to detect rare reactions. 21 The purpose of this case report is to raise awareness among health-care workers about a possible rare side effect that may be associated Essentials • Acquired hemophilia (AHA) is commonly associated with malignancy, autoimmune disease, and pregnancy. Few cases have reported development of AHA after vaccination. • We report a case of AHA after administration of COVID-19 vaccine. We did a literature search for similar cases and examined any link between COVID-19 infection and vaccination in general with development of AHA. • We found two cases of AHA that have occurred after vaccination (not related to COVID-19 vaccination), and similar number of cases that have occurred after COVID-19 infection. • Increase in vigilance regarding extremely rare side effects associated with COVID-19 vaccination is needed. with COVID-19 vaccine and to highlight the need for further vigilance and surveillance worldwide in order to better understand the relationship between autoimmune reactions and COVID-19 vaccination. All authors declare absence of any real or potential conflicts of interest related to this case. Acquired hemophilia A: a concise review Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation A survey of 215 non-hemophilic patients with inhibitors to Factor VIII The first case of acquired hemophilia A associated with SARS-CoV-2 infection Acquired factor VIII haemophilia following influenza vaccination A case of acquired haemophilia following H1N1 vaccination De novo acquired hemophilia as an immune dysregulation phenomenon following SARS-CoV-2 infection Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Vaccination and autoimmune disease: what is the evidence? Influenza vaccine and autoimmunity Transverse myelitis and vaccines: a multi-analysis Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977 Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19) Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19 Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases Immune thrombocytopenic purpura in a patient with Covid-19 COVID-19) Vaccinations -Statistics and Research Pfizer-BioNTech COVID-19 Vaccine. U.S. Food and Drug Administration Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine A case report of acquired hemophilia following COVID-19 vaccine